

116TH CONGRESS
1ST SESSION

H. R. 5357

To amend the Public Health Service Act to authorize a pilot program to develop, expand, and enhance the commercialization of biomedical products, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

DECEMBER 6, 2019

Mr. PETERS introduced the following bill; which was referred to the
Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to authorize a pilot program to develop, expand, and enhance the commercialization of biomedical products, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Innovation Network
5 and Capital Act of 2019”.

1 **SEC. 2. PILOT PROGRAM FOR RESEARCH STARTUPS.**

2 Part A of title IV of the Public Health Service Act
3 (42 U.S.C. 281 et seq.) is amended by adding at the end
4 the following:

5 **“SEC. 404O. PILOT PROGRAM FOR RESEARCH STARTUPS.**

6 “(a) FUNDS.—The Director of NIH shall award
7 grants or contracts to eligible entities to develop, expand,
8 and enhance the commercialization of biomedical products.

9 “(b) ELIGIBLE ENTITY.—In this section, the term
10 ‘eligible entity’ means an entity receiving funding under—

11 “(1) the Small Business Innovation Research
12 program of the National Institutes of Health; or

13 “(2) the Small Business Technology Transfer
14 program of the National Institutes of Health.

15 “(c) USE OF FUNDS.—An eligible entity shall use the
16 funds received through such grant or contract to sup-
17 port—

18 “(1) the Commercialization Readiness Pilot
19 program of the National Institutes of Health;

20 “(2) the Innovation Corps program of the Na-
21 tional Institutes of Health;

22 “(3) the Commercialization Accelerator pro-
23 gram of the National Institutes of Health;

24 “(4) the Commercialization Assistance program
25 of the National Institutes of Health; and

1 “(5) such other programs and activities as the
2 Director of NIH determines to be appropriate, to
3 support the commercialization stage of research,
4 later stage research and development, technology
5 transfer, and commercialization technical assistance.

6 “(d) NIH STARTUP SUPPORT ACCOUNT.—

7 “(1) ESTABLISHMENT.—There is established in
8 the Treasury an account, to be known as the NIH
9 Startup Support Account, for purposes of carrying
10 out this section.

11 “(2) TRANSFER OF FUNDS.—There shall be
12 transferred to the NIH Startup Support Account
13 from the general fund of the Treasury,
14 \$100,000,000 for each of fiscal years 2021 through
15 2025, to be available until expended without further
16 appropriation.”.

○